Acetyl cholinesterase: a potential target for Alzheimer’s disease intervention

Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. The role of treatment is not limited to pharmacology, but also involves many factors, such as the psychological, social, and economic aspects of the patient and family. It is important to consider the use of AChe inhibitors in patients with mild to moderate AD, despite cost issues and in the absence of any other immediate progression. Although there are allots of currently available inhibitor for acetyl cholinesterase but there is no selective potent inhibitor for AD. so, there is an urgent need discover of compounds that are active against Acetyl cholinesterase, along  with there is need of molecular modeling for  identifying functional groups that may be important for inhibiting Acetyl cholinesterase activity

Self-prescribed nutrition supplements for hair loss following laparoscopic sleeve gastrectomy bariatric surgery: extent of the problem in a cohort of Chinese patients

Introductions: Hair loss is common after bariatric surgery. This study analyzes the extent and risk factors of hair loss following laparoscopic sleeve gastrectomy (LSG), and satisfaction of self-prescribed supplements. Methods: All patients of LSG bariatric surgery during June 2013 to August 2016 at Shanghai East Hospital affiliated to Tongji University, Shanghai, China were included in the study. Study variables were- age, gender, preoperative body mass index, hemoglobin, albumin, total cholesterol, iron, zinc, copper, folic acid, vitamin B12, vitamin D, and postoperative excess weight loss (% EWL), time and degree of hair loss, satisfaction of using supplements. Logistic regression was used to analyze risk factors for hair loss. Results: Total of 86 patients underwent LSG. After exclusion data on 54 patients (M=11, F=43) were analyzed. Hair loss was reported by 42/54 (77.8%, M=6, F=36), starting at 3.43±1.36 months and ending at 8.59±3.38. All of 11 severe hair losses were in female. The female gender, preoperative serum folic acid, and %EWL were significant risk factors for hair loss. Hair regrowth was reported by 39/42 (92.86%). The 15 patients who used various self-prescribed iron and zinc supplements reported no satisfactory benefit.  Conclusions: Hair loss was seen in 3/4th of patents after LSG bariatric surgery. Self-prescribed nutrition supplements were used by 1/3 of patients without satisfaction. Female gender, preoperative serum folic acid, and %EWL were significant risk factors for hair loss. Keywords: bariatric surgery, hair loss, laparoscopic sleeve gastrectomy LSG, obesity, nutrition supplement

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. METHODS This phase III, global, double-blind, placebo-controlled trial randomly assigned eligible patients with newly diagnosed advanced or recurrent endometrial cancer 1:1:1 to: carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance (control arm); carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib placebo (durvalumab arm); or carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib (durvalumab + olaparib arm). The primary end points were progression-free survival (PFS) in the durvalumab arm versus control and the durvalumab + olaparib arm versus control. RESULTS Seven hundred eighteen patients were randomly assigned. In the intention-to-treat population, statistically significant PFS benefit was observed in the durvalumab (hazard ratio [HR], 0.71 [95% CI, 0.57 to 0.89]; P = .003) and durvalumab + olaparib arms (HR, 0.55 [95% CI, 0.43 to 0.69]; P < .0001) versus control. Prespecified, exploratory subgroup analyses showed PFS benefit in dMMR (HR [durvalumab v control], 0.42 [95% CI, 0.22 to 0.80]; HR [durvalumab + olaparib v control], 0.41 [95% CI, 0.21 to 0.75]) and pMMR subgroups (HR [durvalumab v control], 0.77 [95% CI, 0.60 to 0.97]; HR [durvalumab + olaparib v control] 0.57; [95% CI, 0.44 to 0.73]); and in PD-L1-positive subgroups (HR [durvalumab v control], 0.63 [95% CI, 0.48 to 0.83]; HR [durvalumab + olaparib v control], 0.42 [95% CI, 0.31 to 0.57]). Interim overall survival results (maturity approximately 28%) were supportive of the primary outcomes (durvalumab v control: HR, 0.77 [95% CI, 0.56 to 1.07]; P = .120; durvalumab + olaparib v control: HR, 0.59 [95% CI, 0.42 to 0.83]; P = .003). The safety profiles of the experimental arms were generally consistent with individual agents. CONCLUSION Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer

Empowering the Path from Stiffness to Recovery in Adhesive Shoulder Capsulitis Complexity

Adhesive shoulder capsulitis, also called arthrofibrosis, is a complex medical condition characterized by excessive scar tissue around the glenohumeral joint, causing stiffness, pain, and reduced functionality. Its historical evolution, from "scapulohumeral periarthritis" to "adhesive capsulitis," traces back to the 20th century. However, the underlying pathology remains unclear, posing diagnostic and treatment challenges. The condition progresses through phases: pain, stiffness, and eventual recovery, each with distinct clinical features. Emerging research shifts the understanding from fibrosis-focused to inflammation and fibrosis combined. Risk factors include age, gender, prior shoulder trauma, and diabetes. It primarily affects older individuals, women, and those with medical comorbidities, particularly diabetes. Diagnosis relies on identifying specific markers like capsule contracture, synovial loss, and adhesions, while differentiation from similar shoulder disorders is crucial. Treatment encompasses non-operative options (physical therapy, medication) and more invasive interventions (manipulation under anesthesia, arthroscopic capsulotomy). This review offers a broad view of adhesive capsulitis, covering its history, causes, risk factors, diagnosis, and various treatments. By exploring its multifaceted dimensions, the aim is to improve understanding and management of this intricate condition, enhancing the lives of those affected

Destructive adsorption of methyl parathion over nanocrystalline MgO

251-255Destructive adsorption of methyl parathion (MP) has been investigated over few transition metal oxides and alkali earth metal oxides. Performance of alkaline earth ox ides have been found to be better than transition metal oxides and best performance has been shown by aerogel method prepared nanocrystalline AP-MgO. The AP-MgO powder has been characterized by XRD, AFM and BET surface area measurements. Destructive adsorption of MP over AP-MgO has been compared with that of activated carbon. Both are found to adsorb methyl parathion effectively. An IR investigation of the surface of treated AP-MgO and activated carbon reveals that activated carbon adsorbs methyl parathion as such in the molecular form and AP-MgO adsorbs it destructively